mitoxantrone has been researched along with Left Ventricular Dysfunction in 11 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tissue Doppler echocardiography was investigated for its applicability in detecting subtle myocardial involvement in multiple sclerosis patients receiving a low dose of mitoxantrone." | 9.14 | Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiographic analysis. ( Borghetti, A; Cappellini, MD; Montanari, E; Moruzzi, P; Pattoneri, P; Pelà, G; Sozzi, F, 2009) |
| "Mitoxantrone (MTX) has been shown to reduce progression of disability and number of clinical exacerbations in patients with progressive multiple sclerosis (MS)." | 7.80 | The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. ( Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014) |
| "Tissue Doppler echocardiography was investigated for its applicability in detecting subtle myocardial involvement in multiple sclerosis patients receiving a low dose of mitoxantrone." | 5.14 | Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiographic analysis. ( Borghetti, A; Cappellini, MD; Montanari, E; Moruzzi, P; Pattoneri, P; Pelà, G; Sozzi, F, 2009) |
| "Mitoxantrone (MXT) is an androstenedione that is used to treat cancers and progressive forms of multiple sclerosis; however, its use is limited by its cardiotoxicity." | 3.85 | Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice. ( Bradley, J; Burn, B; Chuang, G; Coy, DH; Maderdrut, JL; Subramaniam, V; Varner, KJ; Xia, H, 2017) |
| "High-dose mitoxantrone therapy is associated with an excellent remission rate but with a significantly increased risk of clinical and subclinical early cardiotoxicity and heart failure." | 3.83 | Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia-A Velocity Vector Imaging Analysis. ( Ahmed, M; Aurigemma, GP; Cerny, J; Escobar, J; Kane, JL; McGuiness, ME; McManus, DD; Meyer, TE; Nath, R; Ramanathan, M; Shaikh, AY; Shih, J; Suryadevara, S; Tighe, DA; Tripathi, A, 2016) |
| "Mitoxantrone (MTX) has been shown to reduce progression of disability and number of clinical exacerbations in patients with progressive multiple sclerosis (MS)." | 3.80 | The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. ( Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014) |
| "Mitoxantrone is used for aggressive multiple sclerosis (MS), but concerns about safety, including cardiotoxicity and other laboratory measures, prevail." | 3.76 | Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. ( Geddes, J; Isserow, S; Kingwell, E; Koch, M; Leung, B; Rieckmann, P; Tremlett, H, 2010) |
| "Mitoxantrone is a recently approved drug for patients with secondary progressive multiple sclerosis (SPMS)." | 2.71 | Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. ( Abbey, EE; Avasarala, JR; Clifford, DB; Cross, AH; Siegel, BA; Singer, BA, 2003) |
| "No patients experienced congestive heart failure (CHF) before treatment." | 2.41 | Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. ( Butine, MD; Edan, G; Eisenman, S; Ghalie, RG; Gonsette, RE; Goodkin, DE; Hartung, HP; Laurent, M; Mauch, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Subramaniam, V | 1 |
| Chuang, G | 1 |
| Xia, H | 1 |
| Burn, B | 1 |
| Bradley, J | 1 |
| Maderdrut, JL | 1 |
| Coy, DH | 1 |
| Varner, KJ | 1 |
| Podlecka-Piętowska, A | 1 |
| Kochanowski, J | 1 |
| Zakrzewska-Pniewska, B | 1 |
| Opolski, G | 1 |
| Kwieciński, H | 1 |
| Kamińska, AM | 1 |
| Shaikh, AY | 1 |
| Suryadevara, S | 1 |
| Tripathi, A | 1 |
| Ahmed, M | 1 |
| Kane, JL | 1 |
| Escobar, J | 1 |
| Cerny, J | 1 |
| Nath, R | 1 |
| McManus, DD | 1 |
| Shih, J | 1 |
| McGuiness, ME | 1 |
| Tighe, DA | 1 |
| Meyer, TE | 1 |
| Ramanathan, M | 1 |
| Aurigemma, GP | 1 |
| Pattoneri, P | 1 |
| Sozzi, F | 1 |
| Pelà, G | 1 |
| Montanari, E | 1 |
| Moruzzi, P | 1 |
| Borghetti, A | 1 |
| Cappellini, MD | 1 |
| Dörr, J | 1 |
| Bitsch, A | 1 |
| Schmailzl, KJ | 1 |
| Chan, A | 1 |
| von Ahsen, N | 1 |
| Hummel, M | 1 |
| Varon, R | 1 |
| Lill, CM | 1 |
| Vogel, HP | 1 |
| Zipp, F | 1 |
| Paul, F | 1 |
| Kingwell, E | 1 |
| Koch, M | 1 |
| Leung, B | 1 |
| Isserow, S | 1 |
| Geddes, J | 1 |
| Rieckmann, P | 1 |
| Tremlett, H | 1 |
| Le Page, E | 1 |
| Leray, E | 1 |
| Edan, G | 2 |
| Ghalie, RG | 1 |
| Laurent, M | 1 |
| Mauch, E | 1 |
| Eisenman, S | 1 |
| Hartung, HP | 1 |
| Gonsette, RE | 1 |
| Butine, MD | 1 |
| Goodkin, DE | 1 |
| Avasarala, JR | 1 |
| Cross, AH | 1 |
| Clifford, DB | 1 |
| Singer, BA | 1 |
| Siegel, BA | 1 |
| Abbey, EE | 1 |
| Kahles, H | 1 |
| Bastian, HJ | 1 |
| Schiffmann, O | 1 |
| Geck, M | 1 |
| Helmke, FR | 1 |
| Golz, N | 1 |
| Feldman, EJ | 1 |
| Seiter, K | 1 |
| Traganos, F | 1 |
| Darzynkiewicz, Z | 1 |
| Goff, H | 1 |
| Pozzuoli, M | 1 |
| Baskind, P | 1 |
| Santos, S | 1 |
| Ahmed, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)[NCT01627938] | Phase 2 | 50 participants (Anticipated) | Interventional | 2012-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitoxantrone and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.
Topics: Adolescent; Adult; Age Factors; Aged; Chi-Square Distribution; Confidence Intervals; Drug Administra | 2002 |
3 trials available for mitoxantrone and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiographic analysis.
Topics: Adult; Echocardiography, Doppler; Elasticity Imaging Techniques; Female; Humans; Male; Middle Aged; | 2009 |
Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.
Topics: Adult; Antineoplastic Agents; Female; Humans; Injections, Intravenous; Male; Middle Aged; Mitoxantro | 2003 |
Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 2000 |
7 other studies available for mitoxantrone and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.
Topics: Animals; Cardiotoxicity; Cell Line, Tumor; Disease Models, Animal; Heart Injuries; Humans; Mice; Mit | 2017 |
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Topics: Adult; Antineoplastic Agents; Biomarkers; Cardiomyopathies; Female; Heart Diseases; Heart Failure; H | 2014 |
Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia-A Velocity Vector Imaging Analysis.
Topics: Aged; Antineoplastic Agents; Causality; Comorbidity; Echocardiography; Elasticity Imaging Techniques | 2016 |
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
Topics: Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tr | 2009 |
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
Topics: Adult; Age Factors; Analgesics; Anemia; Female; Follow-Up Studies; Humans; Liver Diseases; Male; Mid | 2010 |
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Topics: Adult; Amenorrhea; Female; France; Heart Failure; Humans; Immunologic Factors; Leukemia; Male; Middl | 2011 |
[Mitoxantrone-induced acute left heart failure after intrapleural administration].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Dose-R | 1997 |